CatalystMarker
← board

RLFTY

distress 5/10 · elevated risk
$0.420%today-90% from 52w high
mindmazetherapeutics.com10 employeesFounded 2012Geneva, SwitzerlandBiotechnology
Revenue
pre-revenue
Liquidity
$9M
Runway
1.3 yrs
Shares 1y
-100%

Price & events

-89.6% over 6M
$0.27$2.16$4.05Jan 26Apr 26Jul 267kdilution: 424B3 offering (2026-04-16)
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.0%
1M
-82.4%
3M
-89.6%
6M
1Y
2Y
5Y
-71.8%
All

Overview

Market Cap
$5.30M
Volume
0
52 Week Range
$0.27 – $4.05
Total Shares
12.54M
Float Shares
37.20M

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 12,540,439 · 1 offerings/1y · 0 PIPEs
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.